Literature DB >> 22995758

Towards an integrated molecular and clinical strategy to predict early recurrence in surgically resected non-functional pituitary adenomas.

Nicholas F Marko1, Carolyn Coughlan, Robert J Weil.   

Abstract

Pituitary adenomas (PA) are histologically benign tumors of the sella that are capable of recurrence following resection. No mechanism exists to predict accurately the risk of recurrence in patients with PA following successful gross total surgical resection. We used microarray-based gene expression profiling to search for genotypically distinct subgroups of non-functional PA associated with the early recurrent phenotype. Rigorous phenotypic controls were used to select four patients with PA with early (<12 months) recurrence and seven patients with non-recurrent PA for comparative molecular analysis. Seventy genes with differential expression patterns between the phenotypic groups were identified, although this required some relaxation of rigid multiple-testing corrections. While some of these genes may therefore represent statistical false discoveries attributable to limited sample size, the CHL1 gene has a differential expression patterns that suggests a potential role as a predictor of recurrence phenotype. Transcriptome-level differences between early recurrent and non-recurrent non-functional PA appear to be subtle, although CHL1 expression may be a candidate for further study as a class discriminator. This suggests two possibilities with regard to recurrence; (i) that microscopic residual disease unidentifiable either by the surgeon or by current neuroimaging strategies may serve as a focus for early recurrence or that biological differences in recurrence phenotypes may occur outside of the transcriptome. These findings are useful for focusing future investigations into the clinical and biological mechanisms of PA recurrence as well as for development of strategies designed to predict prospectively these recurrence phenotypes.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22995758     DOI: 10.1016/j.jocn.2012.01.038

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  5 in total

Review 1.  Prognostic factors of regrowth in nonfunctioning pituitary tumors.

Authors:  Gerald Raverot; Alexandre Vasiljevic; Emmanuel Jouanneau
Journal:  Pituitary       Date:  2018-04       Impact factor: 4.107

2.  The missing link: studying the alternative TGF-β pathway provides a unifying theory for different components of diabetic nephropathy.

Authors:  Xiaoyi Zheng; Vivek Bhalla
Journal:  Diabetes       Date:  2015-06       Impact factor: 9.461

3.  CHL1 Is Expressed and Functions as a Malignancy Promoter in Glioma Cells.

Authors:  Zhai Yang; Qing Xie; Cheng-Liang Hu; Qiong Jiang; Hui-Fan Shen; Melitta Schachner; Wei-Jiang Zhao
Journal:  Front Mol Neurosci       Date:  2017-10-17       Impact factor: 5.639

Review 4.  Stem Cells in Pituitary Tumors: Experimental Evidence Supporting Their Existence and Their Role in Tumor Clinical Behavior.

Authors:  Giovanna Mantovani; Elena Giardino; Donatella Treppiedi; Rosa Catalano; Federica Mangili; Anna Spada; Maura Arosio; Erika Peverelli
Journal:  Front Endocrinol (Lausanne)       Date:  2019-10-25       Impact factor: 5.555

5.  Identification of driver genes and key pathways of non-functional pituitary adenomas predicts the therapeutic effect of STO-609.

Authors:  Bo Wu; Shanshan Jiang; Xinhui Wang; Sheng Zhong; Yiming Bi; Dazhuang Yi; Ge Liu; Fangfei Hu; Gaojing Dou; Yong Chen; Yi Wu; Jiajun Dong
Journal:  PLoS One       Date:  2020-10-29       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.